Clinical evidence for Picterus Jaundice Pro

Since 2012 the method has moved from feasibility research to a CE marked medical device, studied with parents, midwives and clinicians on several continents.

White paper by Yoxall

"Picterus Jaundice Pro as a screening tool for neonatal jaundice", summarising 790 newborns across 8 international studies.

Strong correlation

Picterus Jaundice Pro showed a strong correlation with laboratory bilirubin measurements (TSB). The device identified all infants requiring phototherapy within this study cohort.

20 to 35%

Modelled estimates suggested a potential reduction of approximately 20 to 35% in TSB measurements. Further validation in an independent population is recommended.

Peer-reviewed publications

  1. 2026Evaluating the Picterus Jaundice Pro App for Neonatal Jaundice Screening by Parents: Prospective Mixed Methods Study
  2. 2025Advancing neonatal jaundice screening with mHealth: a mixed-methods randomised controlled feasibility study
  3. 2025Validation of a Mobile Health Device for Neonatal Jaundice Screening: A Cross-Sectional Study
  4. 2025Smartphone-based screening of neonatal jaundice in three populations in low and middle-income countries
  5. 2024Neonatal jaundice detection in low-resource Mexican settings: possibilities and barriers for innovation with mobile health
  6. 2023Healthcare workers' perceptions about the use of mobile health technologies in public health facilities in Lagos, Nigeria
  7. 2023Iterative Development, Validation, and Certification of a Smartphone System to Assess Neonatal Jaundice
  8. 2020Bilirubin estimates from smartphone images of newborn infants' skin correlated highly to serum bilirubin levels

From a Trondheim lab to newborns worldwide

Picterus was founded in 2015 in Trondheim, Norway, to ensure a healthy start for every child, anywhere and anytime.

  1. 2012 to 2016

    Concept and feasibility research.

  2. 2017 to 2020

    Clinical validation and patented technology.

  3. 2021 to 2022

    First CE marked medical device.

  4. 2023 to 2024

    Expanded clinical use and usability improvements.

  5. 2025 onwards

    Next-generation model and broader inclusivity. Picterus Newborn Health, our non-profit arm, is established.

Need the full papers or the white paper?

We share publications, regulatory documents and device requirements with clinicians, distributors and health authorities.

Request documents

contact@picterus.com · +47 480 50 777